dc.contributor.author | Schmidt, MK | |
dc.contributor.author | Hogervorst, F | |
dc.contributor.author | van Hien, R | |
dc.contributor.author | Cornelissen, S | |
dc.contributor.author | Broeks, A | |
dc.contributor.author | Adank, MA | |
dc.contributor.author | Meijers, H | |
dc.contributor.author | Waisfisz, Q | |
dc.contributor.author | Hollestelle, A | |
dc.contributor.author | Schutte, M | |
dc.contributor.author | van den Ouweland, A | |
dc.contributor.author | Hooning, M | |
dc.contributor.author | Andrulis, IL | |
dc.contributor.author | Anton-Culver, H | |
dc.contributor.author | Antonenkova, NN | |
dc.contributor.author | Antoniou, AC | |
dc.contributor.author | Arndt, V | |
dc.contributor.author | Bermisheva, M | |
dc.contributor.author | Bogdanova, NV | |
dc.contributor.author | Bolla, MK | |
dc.contributor.author | Brauch, H | |
dc.contributor.author | Brenner, H | |
dc.contributor.author | Brüning, T | |
dc.contributor.author | Burwinkel, B | |
dc.contributor.author | Chang-Claude, J | |
dc.contributor.author | Chenevix-Trench, G | |
dc.contributor.author | Couch, FJ | |
dc.contributor.author | Cox, A | |
dc.contributor.author | Cross, SS | |
dc.contributor.author | Czene, K | |
dc.contributor.author | Dunning, AM | |
dc.contributor.author | Fasching, PA | |
dc.contributor.author | Figueroa, J | |
dc.contributor.author | Fletcher, O | |
dc.contributor.author | Flyger, H | |
dc.contributor.author | Galle, E | |
dc.contributor.author | García-Closas, M | |
dc.contributor.author | Giles, GG | |
dc.contributor.author | Haeberle, L | |
dc.contributor.author | Hall, P | |
dc.contributor.author | Hillemanns, P | |
dc.contributor.author | Hopper, JL | |
dc.contributor.author | Jakubowska, A | |
dc.contributor.author | John, EM | |
dc.contributor.author | Jones, M | |
dc.contributor.author | Khusnutdinova, E | |
dc.contributor.author | Knight, JA | |
dc.contributor.author | Kosma, V-M | |
dc.contributor.author | Kristensen, V | |
dc.contributor.author | Lee, A | |
dc.contributor.author | Lindblom, A | |
dc.contributor.author | Lubinski, J | |
dc.contributor.author | Mannermaa, A | |
dc.contributor.author | Margolin, S | |
dc.contributor.author | Meindl, A | |
dc.contributor.author | Milne, RL | |
dc.contributor.author | Muranen, TA | |
dc.contributor.author | Newcomb, PA | |
dc.contributor.author | Offit, K | |
dc.contributor.author | Park-Simon, T-W | |
dc.contributor.author | Peto, J | |
dc.contributor.author | Pharoah, PDP | |
dc.contributor.author | Robson, M | |
dc.contributor.author | Rudolph, A | |
dc.contributor.author | Sawyer, EJ | |
dc.contributor.author | Schmutzler, RK | |
dc.contributor.author | Seynaeve, C | |
dc.contributor.author | Soens, J | |
dc.contributor.author | Southey, MC | |
dc.contributor.author | Spurdle, AB | |
dc.contributor.author | Surowy, H | |
dc.contributor.author | Swerdlow, A | |
dc.contributor.author | Tollenaar, RAEM | |
dc.contributor.author | Tomlinson, I | |
dc.contributor.author | Trentham-Dietz, A | |
dc.contributor.author | Vachon, C | |
dc.contributor.author | Wang, Q | |
dc.contributor.author | Whittemore, AS | |
dc.contributor.author | Ziogas, A | |
dc.contributor.author | van der Kolk, L | |
dc.contributor.author | Nevanlinna, H | |
dc.contributor.author | Dörk, T | |
dc.contributor.author | Bojesen, S | |
dc.contributor.author | Easton, DF | |
dc.date.accessioned | 2019-01-17T11:01:58Z | |
dc.date.issued | 2016-08-10 | |
dc.identifier.citation | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34 (23), pp. 2750 - 2760 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3013 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/jco.2016.66.5844 | |
dc.description.abstract | PURPOSE: CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. PATIENTS AND METHODS: CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies. RESULTS: Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center-based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 × 10(-20)). The OR was higher for estrogen receptor (ER)-positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 × 10(-21)]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 × 10(-4)). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom. CONCLUSION: These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up. | |
dc.format | Print-Electronic | |
dc.format.extent | 2750 - 2760 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Genetic Predisposition to Disease | |
dc.subject | Receptors, Estrogen | |
dc.subject | Receptors, Progesterone | |
dc.subject | Odds Ratio | |
dc.subject | Risk Assessment | |
dc.subject | Case-Control Studies | |
dc.subject | Age Factors | |
dc.subject | Sequence Deletion | |
dc.subject | Heterozygote | |
dc.subject | Homozygote | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Checkpoint Kinase 2 | |
dc.title | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1200/jco.2016.66.5844 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | |
pubs.issue | 23 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genetic Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genetic Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.publication-status | Published | |
pubs.volume | 34 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Functional Genetic Epidemiology | |
icr.researchteam | Aetiological Epidemiology | |
dc.contributor.icrauthor | Fletcher, Olivia | |
dc.contributor.icrauthor | Jones, Michael | |
dc.contributor.icrauthor | Swerdlow, Anthony | |